{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.375","value":"2.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"}],"units":"Participants"}],"description":"Canakinumab concentration was analyzed in serum by means of a competitive Enzyme-linked immunosorbent assay (ELISA) assay with a lower limit of quantification (LOQ) at 100 ng/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Canakinumab 150 mg"}],"paramType":"MEAN","populationDescription":"Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"12 weeks post-dose","title":"Pharmacokinetic Concentrations","type":"SECONDARY","unitOfMeasure":"µg/mL"}